These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26875154)

  • 1. Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens.
    Veal GJ; Errington J; Sastry J; Chisholm J; Brock P; Morgenstern D; Pritchard-Jones K; Chowdhury T
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):685-92. PubMed ID: 26875154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin therapeutic monitoring in preterm and full-term neonates.
    Veal GJ; Errington J; Hayden J; Hobin D; Murphy D; Dommett RM; Tweddle DA; Jenkinson H; Picton S
    Eur J Cancer; 2015 Sep; 51(14):2022-30. PubMed ID: 26232270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.
    Thomas F; Veal GJ; El Balkhi S; Lafont T; Picard N; Brugières L; Chatelut E; Piguet C
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):361-365. PubMed ID: 29922990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma.
    Picton SV; Keeble J; Holden V; Errington J; Boddy AV; Veal GJ
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):749-52. PubMed ID: 18607591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients.
    Barnett S; Hellmann F; Parke E; Makin G; Tweddle DA; Osborne C; Hempel G; Veal GJ
    Eur J Cancer; 2022 Mar; 164():127-136. PubMed ID: 34657763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance.
    Nijstad AL; Barnett S; Lalmohamed A; Bérénos IM; Parke E; Carruthers V; Tweddle DA; Kong J; Zwaan CM; Huitema ADR; Veal GJ
    Eur J Cancer; 2022 Mar; 164():137-154. PubMed ID: 34865945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy.
    Veal GJ; English MW; Grundy RG; Shakespeare C; Glaser A; Waters F; Holden V; O'Meara A; Michalski A; Howe K; Cole S; Boddy AV
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):295-300. PubMed ID: 15133627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom.
    Barnett S; Kong J; Makin G; Veal GJ
    Br J Clin Pharmacol; 2021 Feb; 87(2):256-262. PubMed ID: 32519769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
    Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
    Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
    Thomas H; Boddy AV; English MW; Hobson R; Imeson J; Lewis I; Morland B; Pearson AD; Pinkerton R; Price L; Stevens M; Newell DR
    J Clin Oncol; 2000 Nov; 18(21):3614-21. PubMed ID: 11054434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy in newborns and preterm babies.
    Veal GJ; Boddy AV
    Semin Fetal Neonatal Med; 2012 Aug; 17(4):243-248. PubMed ID: 22464845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
    Loh GW; Ting LS; Ensom MH
    Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
    de Jongh FE; Verweij J; Loos WJ; de Wit R; de Jonge MJ; Planting AS; Nooter K; Stoter G; Sparreboom A
    J Clin Oncol; 2001 Sep; 19(17):3733-9. PubMed ID: 11533095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis.
    Nijstad AL; van Eijkelenburg NKA; Kraal KCJM; Meijs MJM; de Kanter CTMM; Lilien MR; Huitema ADR
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):445-449. PubMed ID: 32816154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
    Mehrotra N; Tang L; Phelps SJ; Meibohm B
    Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
    Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants.
    Hutson JR; Weitzman S; Schechter T; Arceci RJ; Kim RB; Finkelstein Y
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):709-22. PubMed ID: 22509821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical treatment guide for dose individualisation in cancer chemotherapy.
    Canal P; Chatelut E; Guichard S
    Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Optimalisation of netilmicin dosage based on therapeutic drug monitoring during the first days of life in very preterm neonates (gestational age 23-32 weeks)].
    Rutkowska M; Kamińska E; Piekarczyk A; Nowicka K; Polak K; Nowakowska-Szyrwińska E; Szamotulska K
    Med Wieku Rozwoj; 2009; 13(4):252-9. PubMed ID: 20081273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
    Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
    Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.